NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Abiraterone for treating metastatic hormonerelapsed prostate cancer before chemotherapy is indicated

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

First appraisal consultation document (May 2014)

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

The scope remit and population referred to men with prostate cancer. An issue was raised during the scoping workshop regarding people who have undergone gender reassignment. People who have undergone a male-to-female gender reassignment will still have a prostate and can therefore develop cancer of the prostate. The issue raised was that those people may be uncomfortable accessing a male urology clinic. Additionally, using the term 'men' in the remit and population section would not be appropriate for this population.

The Committee was aware of this issue and agreed its recommendations should apply to '*people*' with prostate cancer.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No further equalities issues were raised in the submissions, expert statements or academic report.

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Issue date: March 2016 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No further equalities issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The Committee's consideration of equality issues has been described in the Summary of Appraisal Committee's key conclusions table.

Date: 06 05 2014

First final appraisal determination (August 2014)

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

None.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

N/A

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

N/A

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Ν	I /	A
	•/	<i>'</i> '

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's consideration of equality issues has been described in the Summary of Appraisal Committee's key conclusions table.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 15 07 2014

Second appraisal consultation document (December 2015)

1. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No further equalities issues were raised.

2. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No further equalities issues were identified by the Committee.

3. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

4. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Issue date: March 2016

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The Committee's consideration of equality issues has been described in the Summary of Appraisal Committee's key conclusions table.

Approved by Associate Director (name): Melinda Goodall

Date: 9th December 2015

Second final appraisal determination (March 2016)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

None.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's consideration of equality issues has been described in the

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Issue date: March 2016 Summary of Appraisal Committee's key conclusions table.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 29th February 2016